💊 Oral esketamine maintenance treatment shows sustained symptom stability in treatment-resistant depression (Smith-Apeldoorn et al., Depression and Anxiety) — 10/29/26
TL;DR: Observational study of 93 severe TRD patients found at-home oral esketamine maintenance (mean 20.8 months) sustained symptom stability, with 60% of those meeting MCID criteria maintaining response and treatment generally safe and well-tolerated.
🍽️ Global burden of anorexia nervosa and bulimia nervosa reaches 18.1M people in 2023 (Bai et al., JAMA Psychiatry) — 10/28/26
TL;DR: GBD 2023 analysis estimates 18.1M people globally live with anorexia or bulimia (69% female, 41% aged 10-24), with cases up 71% since 1990 and highest prevalence in Australasia and Western Europe; forecasts predict continued increases through 2050.
📞 SPARC trial: adolescents benefit from Caring Contacts texts, adults from Instrumental Support Calls for suicide prevention (Radin et al., American Journal of Psychiatry) — 10/28/26
TL;DR: Pragmatic RCT of 1,520 at-risk adolescents and adults from EDs and primary care found adults had lower 6-month suicidal ideation/behavior with Instrumental Support Calls, while adolescents had lower 12-month SI/SB with Caring Contacts texts.
🧠 Nature study: emotion regulation capacity lacks a shared neural signature (Sicorello, Zaehringer, Kraynak et al., Nature) — 10/28/26
TL;DR: Preregistered consortium analysis of 40 fMRI datasets (n=2,175) found trait questionnaires, task-based affective ratings, and amygdala down-regulation don’t converge on a common core of cognitive reappraisal, challenging neural biomarker assumptions for emotion regulation.